Table 1.
Baseline demographic details and tumor characteristics of patients treated with adjuvant intravesical BCG Danish 1331 and BCG Moscow-I strain for non-muscle invasive bladder cancer.
| Variable | BCG Danish 1331 (n=68) |
BCG Moscow-I (n=46) |
p-Value |
|---|---|---|---|
| Sex, n (%) | |||
| Male | 57 (83.8) | 38 (82.6) | 0.864 |
| Female | 11 (16.2) | 8 (17.4) | |
| Age, median (range), year | 60.5 (34.0–78.0) | 61.5 (38.0–77.0) | 0.794 |
| Past history of TURBT, n (%) | |||
| Nil | 48 (70.6) | 33 (71.7) | 0.894 |
| 1 | 15 (22.1) | 11 (23.9) | |
| ≥2 | 5 (7.4) | 2 (4.3) | |
| Tumor status, n (%) | |||
| pTa | 25 (36.8) | 15 (32.6) | 0.735 |
| pT1 | 38 (55.9) | 25 (54.3) | |
| pTis | 3 (4.4) | 4 (8.7) | |
| pT1+pTis | 2 (2.9) | 2 (4.3) | |
| Tumor risk stratification, n (%) | |||
| Low | 8 (11.8) | 3 (6.5) | 0.723 |
| Intermediate | 33 (48.5) | 24 (52.2) | |
| High | 27 (39.7) | 19 (41.3) | |
BCG, bacillus Calmette-Guerin; TURBT, transurethral resection of bladder tumor.